Company Description: VoxCell is creating human-like vascularized tissue models as a screening platform in drug development; by combining Canada’s first high-resolution 3D bioprinter, VoxCell’s proprietary universal bioinks and VoxCell’s vascularization software. These innovations result in fully vascularized and perfusable tissue models, akin to artificial biopsy samples. The problem we target is the alarming 95% failure rate in drug development, which extends from preclinical stages to phase 3 clinical trials, costing an estimated $60 billion USD annually in failed clinical trials in oncology. This high failure rate primarily stems from the absence of reliable tools that can accurately predict drug candidate behavior in human patients. VoxCell's 3D bioprinted vascularized tissue models offer a transformative solution. They enable early identification of unviable drug candidates, allowing pharmaceutical companies to fail faster and more cost-effectively. By doing so, our solution saves time and resources, benefiting both the pharmaceutical industry and patients waiting for more effective treatments.